Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas

SIMPLE SUMMARY: Tumor mutation burden (TMB) has shown promise as a biomarker for immune checkpoint blockade therapy in some cancers, but not consistently in gliomas. The goal of our study was to systematically investigate the association between TMB, expressed neoantigens, and the tumor immune micro...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Guangyang, Pang, Ying, Merchant, Mythili, Kesserwan, Chimene, Gangalapudi, Vineela, Abdelmaksoud, Abdalla, Ranjan, Alice, Kim, Olga, Wei, Jun S., Chou, Hsien-Chao, Wen, Xinyu, Sindiri, Sivasish, Song, Young K., Xi, Liqiang, Kaplan, Rosandra N., Armstrong, Terri S., Gilbert, Mark R., Aldape, Kenneth, Khan, Javed, Wu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657099/
https://www.ncbi.nlm.nih.gov/pubmed/34885201
http://dx.doi.org/10.3390/cancers13236092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657099/
https://www.ncbi.nlm.nih.gov/pubmed/34885201
http://dx.doi.org/10.3390/cancers13236092

Ejemplares similares